Exploring the Capabilities of a Versatile, Novel, Automated Closed system For Cell and Gene Therapy Manufacturing

Webinar Summary:

New trends and challenges are being identified as more cell and gene therapy institutions move toward clinical trials and into commercialization. Closed manufacturing systems are designed to minimize contamination risks and reduce ISO cleanroom requirements. In combination with digital connectivity, these systems enable repeatable, trackable, and GMP-compliant manufacturing processes.

In this talk, we will discuss the value of moving towards modular, closed-system technologies designed to enable scalable and cost-effective manufacturing, with a highlight of the Gibco CTS Rotea Counterflow Centrifugation System, a revolutionary benchtop, closed system which offers exceptional flexibility for cell washing, concentration, and separation by size, with high cell recovery and throughput rate. The compact footprint, process flexibility, and sterile single-use kit allow the system to seamlessly scale with your process, from research through clinical manufacturing.

Watch now to learn about:

The scalability and flexibility of the latest modular closed-system manufacturing technology applied across a range of cell types as well as viral vectors
How to improve both throughput and robustness of key steps including: cell isolation, cell separation by size,cryo preserved cell wash and media exchange, formulation for cryopreservation, RBC lysis or depletion, and viral vector clarification.
How to streamline the transition to GMP manufacture in a cost, time and space efficient manner

Speaker Information:

Premkumar Jayaraman, PhD
Regional Field Applications Scientist, Cell and Gene Therapy (Asia Pacific and Japan) Thermo Fisher Scientific

Sarah Daoudi, MS
Field Application Scientist, Cell and Gene Therapy (North America West) Thermo Fisher Scientific

Exploring the Capabilities of a Versatile, Novel, Automated Closed System for Cell and Gene Therapy Manufacturing

New trends and challenges are being identified as more cell and gene therapy institutions move toward clinical trials and into commercialization. Closed manufacturing systems are designed to minimize contamination risks and reduce ISO cleanroom requirements.

Webinar Summary: